Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Non-Current Assets (2019 - 2025)

C4 Therapeutics' Non-Current Assets history spans 7 years, with the latest figure at $101.0 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 9.94% year-over-year to $101.0 million; the TTM value through Dec 2025 reached $318.4 million, down 23.92%, while the annual FY2025 figure was $101.0 million, 9.94% up from the prior year.
  • Non-Current Assets reached $101.0 million in Q4 2025 per CCCC's latest filing, up from $58.6 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $212.5 million in Q1 2022 to a low of $50.9 million in Q2 2021.
  • Average Non-Current Assets over 5 years is $110.8 million, with a median of $103.9 million recorded in 2024.
  • Peak YoY movement for Non-Current Assets: surged 846.6% in 2021, then crashed 44.68% in 2023.
  • A 5-year view of Non-Current Assets shows it stood at $181.1 million in 2021, then dropped by 20.87% to $143.3 million in 2022, then dropped by 26.54% to $105.3 million in 2023, then dropped by 12.76% to $91.8 million in 2024, then increased by 9.94% to $101.0 million in 2025.
  • Per Business Quant, the three most recent readings for CCCC's Non-Current Assets are $101.0 million (Q4 2025), $58.6 million (Q3 2025), and $71.8 million (Q2 2025).